🔎 Trials Near Me

Domov › Akútna myeloidná leukémia › Ohio › Cleveland

Klinické štúdie Akútna myeloidná leukémia v meste Cleveland, OH

20 štúdií pre Akútna myeloidná leukémia hľadá účastníkov v zariadeniach v meste Cleveland a okolí (do cca 30 míľ). Otvorte štúdiu a zistite, kto sa môže zapojiť a ako kontaktovať tím.

Oficiálny text štúdie (anglicky)

Hľadáte účastníkov do štúdie? Zvýraznite ju na začiatku tejto stránky – $99 na 30 dní →

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Prebieha náborFáza 2
  • Case Western Reserve University, Cleveland
Vek 18 a viac · Všetky pohlavia · Aktualizované 5. 10. 2026 · NCT05564390

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

Prebieha náborFáza 2
  • Case Western Reserve University, Cleveland
Vek 18 až 59 · Všetky pohlavia · Aktualizované 28. 9. 2026 · NCT05554393

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

Prebieha náborFáza 3
  • University Hospitals Cleveland Medical Center, Cleveland
  • Cleveland Clinic, Cleveland
Vek 18 a viac · Všetky pohlavia · Aktualizované 25. 9. 2026 · NCT06852222

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

Prebieha náborFáza 2
  • Case Western Reserve University, Cleveland
Vek 18 až 59 · Všetky pohlavia · Aktualizované 22. 9. 2026 · NCT05554406

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

Prebieha náborFáza 2
  • Case Western Reserve University, Cleveland
Vek 18 a viac · Všetky pohlavia · Aktualizované 22. 9. 2026 · NCT06317649

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Prebieha náborFáza 3
  • Rainbow Babies and Childrens Hospital, Cleveland
  • Cleveland Clinic Foundation, Cleveland
6 Months – 21 Years · Všetky pohlavia · Aktualizované 17. 9. 2026 · NCT04293562

Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood

Prebieha náborFáza 2
  • Case Comprehensive Cancer Center, University Hospitals Cleveland Medical Center Seidman Cancer Center, Cleveland
Vek 18 a viac · Všetky pohlavia · Aktualizované 15. 9. 2026 · NCT06904482

Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies

Prebieha náborFáza 1/2
  • Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland
Vek 18 a viac · Všetky pohlavia · Aktualizované 14. 9. 2026 · NCT03471260

Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia

Prebieha náborFáza 3
  • Rainbow Babies and Childrens Hospital, Cleveland
Vek 1 až 25 · Všetky pohlavia · Aktualizované 4. 9. 2026 · NCT07022678

Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML

Prebieha náborFáza 1
  • Cleveland Clinic, Cleveland
Vek 18 a viac · Všetky pohlavia · Aktualizované 25. 8. 2026 · NCT06533761

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Prebieha náborFáza 1
  • UH Seidman Cancer Center, Cleveland
Vek 18 a viac · Všetky pohlavia · Aktualizované 20. 8. 2026 · NCT06001788

L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML

Prebieha náborFáza 2/3
  • University Hospitals Cleveland Medical Center, Cleveland
Vek 18 až 80 · Všetky pohlavia · Aktualizované 5. 8. 2026 · NCT06788756

Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

Prebieha náborFáza 3
  • The Ohio State University Comprehensive Cancer Center (OSUCCC), Cleveland
Vek 18 až 75 · Všetky pohlavia · Aktualizované 17. 7. 2026 · NCT05429632

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Prebieha náborObservačná štúdia
  • University Hospitals Case Medical Center, Cleveland
  • Cleveland Clinic, Cleveland
Všetky vekové kategórie · Všetky pohlavia · Aktualizované 6. 7. 2026 · NCT01351545

A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML)

Prebieha náborFáza 1
  • Case Western Reserve University, Cleveland
Vek 18 a viac · Všetky pohlavia · Aktualizované 12. 6. 2026 · NCT05834244

Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant

Prebieha náborFáza 1/2
  • Cleveland Clinic Taussig Cancer Center, Case Comprehensive Cancer Center, Cleveland
  • University Hospitals Seidman Cancer, Case Comprehensive Cancer Center, Cleveland
Vek 18 a viac · Všetky pohlavia · Aktualizované 27. 4. 2026 · NCT06129734

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

Prebieha náborFáza 1
  • University Hospitals Cleveland Medical Center, Cleveland
  • Cleveland Clinic Taussig Cancer Institute, Cleveland
Vek 18 a viac · Všetky pohlavia · Aktualizované 13. 3. 2026 · NCT05735184

Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant

Prebieha náborFáza 1
  • Cleveland Clinic Cancer Center, Cleveland
Vek 18 a viac · Všetky pohlavia · Aktualizované 5. 3. 2026 · NCT06543381

Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring

Prebieha náborObservačná štúdia
  • University Hospitals Seidman Cancer Center, Cleveland
Vek 18 a viac · Všetky pohlavia · Aktualizované 23. 2. 2026 · NCT05974150

Štúdie Akútna myeloidná leukémia v iných mestách

Iné štúdie v Cleveland

Z ClinicalTrials.gov, dáta načítané 6. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.